Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight
New York, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight
The growing interstitial lung disease market is supported by the widespread use of foundational and supportive treatments such as corticosteroids, immunosuppressants, biologics, and adjunct therapies like cough suppressants. At the same time, the introduction of advanced pipeline candidates, including seralutinib (Gossamer Bio/Chiesi Farmaceutici), L606 (Liquidia Corporation), N-115 (Emphycorp), efzofitimod (aTyr Pharma), and others, is expanding the treatment landscape by addressing multiple disease pathways, thereby driving sustained market growth and ongoing therapeutic innovation.
Recently published Interstitial Lung Disease Market Insights report includes a comprehensive understanding of current treatment practices, interstitial lung disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Interstitial Lung Disease Market Summary
Discover which segment dominates ILD market @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-market
Key Factors Driving the Growth of the Interstitial Lung Disease Market
According to Ramandeep Singh, Senior Consultant of Forecasting at DelveInsight, the ILD therapeutic pipeline is undergoing a decisive shift from conventional anti-fibrotic and broad immunosuppressive strategies toward targeted biologics, novel small molecules, and advanced inhaled delivery platforms. Several late- and mid-stage programs now aim to address immune dysregulation, fibrotic signaling, and pulmonary vascular remodeling in a more mechanistically precise manner. BENLYSTA, developed by GSK, represents a shift toward B-cell-targeted therapy in autoimmune-driven interstitial lung disease, particularly systemic sclerosis–associated and connective tissue disease–associated ILD.
Interstitial Lung Disease Market Analysis
Learn more about the top companies working on IPF @ Interstitial Lung Disease Treatment Market
Interstitial Lung Disease Competitive Landscape
Some of the ILD drugs under development include Belimumab (BENLYSTA) (GSK), Treprostinil Palmitil Inhalation Powder (TPIP) (Insmed), Seralutinib (Gossamer Bio/Chiesi Farmaceutici), L606 (Treprostinil Liposome Inhalation Suspension) (Liquidia Corporation), Admilparant (BMS-986278) (Bristol-Myers Squibb), N115 (Nonsteroidal Nasal Spray) (Emphycorp), Efzofitimod (aTyr Pharma), Deupirfenidone (LYT-100) (PureTech Health), Taladegib (ENV-101) (Endeavor Biomedicines), AP01 (Inhaled Pirfenidone) (Avalyn Pharma), and others.
GSK’s Belimumab (BENLYSTA) is a B-lymphocyte stimulator (BLyS)–targeting inhibitor that binds to soluble BLyS, an essential factor for B-cell survival. As a fully human monoclonal antibody, it suppresses BLyS-driven prolonged survival of B cells, including autoreactive ones, and limits their maturation into immunoglobulin-secreting plasma cells.
Currently, belimumab is being assessed in advanced-stage (Phase II/III and Phase III) clinical trials for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and connective tissue disease-associated ILD (CTD-ILD), highlighting the growing focus on B-cell-directed immunomodulatory therapies to maintain lung function and slow fibrotic progression.
Gossamer Bio/Chiesi Farmaceutici’s Seralutinib is an inhaled inhibitor of PDGFRα/β, CSF1R, and c-KIT, formulated as a dry powder for delivery via inhalation. It is being developed as a potential treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD).
Liquidia Corporation’s L606, developed in collaboration with Pharmosa Biopharm, is an investigational liposomal inhalation formulation of treprostinil designed for sustained release. This approach aims to enhance pulmonary delivery of treprostinil in patients with PAH and PH-ILD.
Insmed’s Treprostinil palmitil inhalation powder (TPIP) is a dry powder prodrug formulation in which treprostinil is esterified to a 16-carbon chain. It represents a potentially differentiated prostanoid therapy under investigation for PAH, PH-ILD, and other severe pulmonary conditions. Administered באמצעות a capsule-based inhalation device, TPIP remains an investigational product and has not yet received approval for any indication worldwide.
The anticipated launch of these emerging interstitial lung disease therapies are poised to transform the interstitial lung disease market landscape in the coming years. As these cutting-edge interstitial lung disease therapies continue to mature and gain regulatory approval, they are expected to reshape the interstitial lung disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about late-stage ILD therapies, visit @ Interstitial Lung Disease Medication
Recent Developments in the Interstitial Lung Disease Market
What is Interstitial Lung Disease?
Interstitial lung disease refers to a large and diverse group of lung disorders that primarily affect the interstitium, the delicate, lace-like network of tissue surrounding the air sacs in the lungs. In ILD, this tissue becomes inflamed and/or scarred, leading to reduced lung elasticity and impaired oxygen transfer into the bloodstream. Common causes include long-term exposure to environmental or occupational irritants, autoimmune diseases, certain medications, and infections, although in some cases the cause remains unknown, as seen in Idiopathic Pulmonary Fibrosis. Patients typically present with symptoms such as persistent dry cough, shortness of breath, and fatigue, which tend to worsen over time. While many forms of ILD are chronic and progressive, early diagnosis and appropriate management can help slow disease progression and improve quality of life.
Interstitial Lung Disease Epidemiology Segmentation
The interstitial lung disease epidemiology section provides insights into the historical and current interstitial lung disease patient pool and forecasted trends for the leading markets. According to DelveInsight’s estimates, in 2025, the US reported nearly 520,000 diagnosed prevalent cases of ILD.
The interstitial lung disease market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
Download the report to understand best-selling drugs for pulmonary fibrosis @ Interstitial Lung Disease Treatment Options
Scope of the Interstitial Lung Disease Market Report
Discover more about unmet needs in interstitial lung disease @ Interstitial Lung Disease Clinical Trials
Table of Contents
Related Reports
Interstitial Lung Disease Epidemiology
Interstitial Lung Disease Clinical Trial Analysis
Interstitial Lung Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key interstitial lung disease companies, including AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical, Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others.
Pulmonary Hypertension associated with Interstitial Lung Disease Market
Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PH-ILD companies including Pharmosa BioPharm, Liquidia Corporation, Insmed, Roivant Sciences, Pulmovant, Halo Biosciences, Respira Therapeutics, Gossamer Bio, and others.
Connective Tissue Disease associated with Interstitial Lung Disease Market
Connective Tissue Disease associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTD-ILD companies, including Boehringer Ingelheim, Roche, Genentech, Bristol Myers Squibb, Novartis, Pfizer, Gilead Sciences, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Merck & Co., Sanofi, Eli Lilly and Company, AbbVie, Celgene (now part of Bristol Myers Squibb), Vertex Pharmaceuticals, Biogen, Amgen, Takeda Pharmaceutical Company, Daiichi Sankyo, Astellas Pharma, and others.
Progressive Fibrosing Interstitial Lung Disease Market
Progressive Fibrosing Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key progressive fibrosing interstitial lung disease companies including Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche, Pliant Therapeutics, United Therapeutics, Vicore Pharma AB, and others.
Systemic Sclerosis associated Lung Disease Market
Systemic Sclerosis associated Lung Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key systemic sclerosis associated lung disease companies including Genentech Inc., Boehringer Ingelheim, Prometheus Biosciences Inc., Roche, Acceleron Pharma, Talaris Therapeutics, Kadmon Corporation, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.